Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NA-911
- Development stage
- Unknown
- Lead developer
- Biomed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NA-911 is an orally administered small molecule neuroprotective and neurogenic drug candidate developed by Biomed Industries (formerly NeuroActiva) for the treatment and prevention of stroke. As an analog of Biomed's lead compound NA-831, NA-911 is designed to cross the blood-brain barrier and stimulate adult neurogenesis, specifically targeting progenitor cells in the subventricular zone (SVZ) to facilitate the repair of damaged brain tissue. It aims to mitigate the neurological damage caused by ischemic or hypoxic injury and improve motor and cognitive recovery, with a therapeutic window of up to 12 hours post-stroke. The drug is currently being evaluated in Phase 2 clinical trials.
Beyond the preview
Go deeper on NA-911.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NA-911.